Strategies for Treating 2nd Line RCC Patients

Strategies for Treating 2nd Line RCC Patients

obr

6 months
54 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute discusses strategies for treating 2nd line renal cell carcinoma (RCC) patients following I-O in the 1st line.
Up Next Autoplay
The Role of Immunotherapy in Bladder Cancer
The Role of Immunotherapy in Bladder Cancer
Category: Bladder Cancer
3 Views
cancergrace 2 weeks
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Category: Bladder Cancer
12 Views
Cancer-News 2 weeks
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
Category: Bladder Cancer
51 Views
Cancer-News 3 months
EV-103 Phase I Trial Presented at #ESMO19
EV-103 Phase I Trial Presented at #ESMO19
Category: Bladder Cancer
25 Views
Cancer-News 3 months
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Category: Bladder Cancer
50 Views
Cancer-News 4 months
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Category: Bladder Cancer
26 Views
Cancer-News 4 months
Treating Newly Diagnosed RCC Patients
Treating Newly Diagnosed RCC Patients
Category: Bladder Cancer
61 Views
obr 6 months
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Category: Bladder Cancer
115 Views
obr 6 months
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Category: Bladder Cancer
52 Views
obr 6 months